Find and Pitch Jounalists, Get Your Story Covered

Tags: leadership pharma Research & Development research-development biotech

	Profile	Recent Articles on Subject
1	Alex Carchidi Motley Fool Writer, consultant, entrepreneur. Motley Fool. Boston, Massachusetts writingconsultingentrepreneurshipfinance	Investing in Biotech or Pharma Stocks? Pay Attention to These 3 Things and You'll Win More - 5 days ago This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks - 9 months ago
2	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 6 days ago STAT+: Up and down the ladder: The latest comings and goings - 27 days ago STAT+: Pharmalittle: We’re reading about FTC scrutiny of a Novo deal, a Genentech reorganization, and more - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: European Parliament votes in favor of updated pharma legislation, prompting mixed reactions - 5 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 5 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 5 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 6 months ago STAT+: Pharmalittle: We’re reading about a tossed PhRMA lawsuit, secrecy clauses, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 9 months ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - 9 months ago STAT+: 3 issues to watch in pharma in 2024 - 9 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 10 months ago STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - 10 months ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - 11 months ago STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail - 11 months ago
3	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Who’s winning in biotech’s tight market? - 6 days ago What 3 layoff stories reveal about pharma’s troubles - 13 days ago Pharma’s ‘it’ therapy — a new drug class gaining steam - 15 days ago What pharma has learned from AI - about 2 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 3 months ago Where competition is heating up in pharma - 4 months ago 3 big recent trial flops - 5 months ago Viral return: 3 U.S. cases concerning experts - 6 months ago The biggest questions hanging over pharma in 2024 - 8 months ago Pharma execs sound off on trends and policies they’re tracking in 2024 - 8 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - 8 months ago 10 of our most read articles in 2023 - 9 months ago PharmaVoice 100s: Entrepreneurs - 11 months ago PharmaVoice 100s: Clinical trial gurus - 11 months ago 3 recent FDA adcomm rejections — and why they matter - 12 months ago
4	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	3 FDA approval dates to watch in the year’s final push - 8 days ago Pharma’s concerns pile up months after Supreme Court’s landmark Chevron decision - 29 days ago Read to lead: 6 books pharma execs swear by - about 2 months ago Behind Big Pharma’s layoffs — is there an end in sight? - 3 months ago Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies - 4 months ago As AI proliferates in pharma, regulators look to catch up in clinical trials - 5 months ago 4 offbeat biotechs making a splash in the life sciences - 5 months ago 5 Big Pharma CEOs who saw major pay bumps in 2023 - 6 months ago COVID vaccine giants Moderna and Pfizer employ divergent tactics for the next chapter - 6 months ago Could pharma’s legal attack on the IRA succeed in killing price negotiations? - 7 months ago
5	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Is pharma still fearful of the Inflation Reduction Act? - about 1 month ago The biotech news you missed this week - 2 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 4 months ago The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - 9 months ago
6	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	Merck lays off workers amid rough pharma job market - about 2 months ago
7	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	A biotech’s binary bet ends badly - 3 months ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - 7 months ago
8	Alexandra Pecci Pharma Voice Leading community for life sciences leaders. Washington, D.C. pharmaceuticalslife sciencescommunity building	How a 15-year-old Genzyme drug shortage became a legal smorgasbord of pharma’s thorniest issues - 7 months ago 4 biotechs to watch in 2024 - 7 months ago 5 noteworthy pharma AI investments in 2023 - 9 months ago 4 historic FDA approvals from 2023 - 10 months ago The fortunes and flops of pharma M&A - 10 months ago Biopharma’s top 5 IPOs of 2023 (so far) - 10 months ago 5 of the best paid biopharma CEOs - 10 months ago In a record year for biotech bankruptcy, here are 3 companies that went under - 11 months ago
9	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - 7 months ago
10	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - 7 months ago Eli Lilly’s latest $1.4 billion deal might come unglued - 10 months ago

Journalists covering BioPharma, Legal, Pharma